Time to Onset of Action of Vardenafil: A Retrospective Analysis of the Pivotal Trials for the Orodispersible and Film-Coated Tablet Formulations

被引:20
|
作者
Debruyne, Frans M. J. [1 ]
Gittelman, Marc [2 ]
Sperling, Herbert [3 ]
Boerner, Matthias [4 ]
Beneke, Manfred [5 ]
机构
[1] Andros Mannenklin, Arnhem, Netherlands
[2] S Florida Med Res, Dept Urol, Aventura, FL USA
[3] Kliniken Maria Hilf GmbH, Monchengladbach, Germany
[4] Bayer HealthCare, Berlin, Germany
[5] Bayer HealthCare, Elberfeld, Germany
来源
JOURNAL OF SEXUAL MEDICINE | 2011年 / 8卷 / 10期
关键词
Erectile Dysfunction; Orodispersible Tablet; Phosphodiesterase Type 5 Inhibitor; Time to Onset of Action; Vardenafil; RADICAL RETROPUBIC PROSTATECTOMY; ERECTILE DYSFUNCTION; DOUBLE-BLIND; EFFICACY; SAFETY; MEN; MANAGEMENT; INHIBITOR; THERAPY; UPDATE;
D O I
10.1111/j.1743-6109.2011.02462.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Patients and physicians consider a rapid onset of action to be an important attribute of oral pharmacotherapy for erectile dysfunction. Aim. To investigate the time to onset of action of a new orodispersible tablet (ODT) formulation of vardenafil. Methods. A post hoc integrated analysis was performed on data from two 12-week, double-blind, multicenter, randomized, parallel-group, placebo-controlled phase III trials of 10 mg vardenafil ODT. Data for the vardenafil film-coated tablet were generated from a retrospective integrated analysis at week 12 of four double-blind, multicenter, randomized, parallel-group, fixed-dose, placebo-controlled phase III trials. Time intervals (in 15-, 30-, and 60-minute increments, up to >= 6 hours after study medication intake) were determined for the period between dosing and start of sexual activity (with the intention of intercourse). Main Outcome Measures. The total number of sexual intercourse attempts and Sexual Encounter Profile question 3 (SEP3) success rates were calculated per time interval. Results. Within 15 minutes postdosing, mean per-patient SEP3 success rates were 62.5% (vardenafil ODT) vs. 29.4% (placebo), with corresponding overall SEP3 success rates of 59.8% and 38.2%. In this time interval, 5.3% vs. 2.8% of all sexual activity attempts were initiated by subjects taking vardenafil ODT (n = 89) or placebo (n = 62), respectively. At 16-30 minutes postdosing, SEP3 success rates were 65.3% and 32.6% (mean per-patient) and 70.2% and 51.0% (overall) for vardenafil ODT vs. placebo, respectively, with a corresponding 10.4% and 8.7% of all sexual activity attempts being made by subjects taking vardenafil ODT (n = 170) or placebo (n = 118). Comparable results were observed for vardenafil 10 and 20 mg film-coated tablet at corresponding time intervals. Conclusions. Vardenafil ODT shows a rapid onset of action comparable with that of vardenafil film-coated tablet. In those men who begin sexual activity within 30 minutes after dosing, the majority of sexual attempts lead to successful intercourse. Debruyne FMJ, Gittelman M, Sperling H, Borner M, and Beneke M. Time to onset of action of vardenafil: A retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med 2011;8:2912-2923.
引用
收藏
页码:2912 / 2923
页数:12
相关论文
共 25 条
  • [1] Re: Time to Onset of Action of Vardenafil: A Retrospective Analysis of the Pivotal Trials for the Orodispersible and Film-Coated Tablet Formulations Editorial Comment
    Seftel, Allen D.
    JOURNAL OF UROLOGY, 2012, 187 (05): : 1787 - 1787
  • [2] TIME TO ONSET OF ACTION OF VARDENAFIL ORODISPERSIBLE AND FILM-COATED TABLETS: A RETROSPECTIVE ANALYSIS OF THE PIVOTAL TRIALS
    Debruyne, F.
    Gittelman, M.
    Sperling, H.
    Boerner, M.
    Beneke, M.
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 : 373 - 373
  • [3] Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials
    Capogrosso, Paolo
    Ventimiglia, Eugenio
    Boeri, Luca
    Serino, Alessandro
    Russo, Andrea
    La Croce, Giovanni
    Capitanio, Umberto
    Deho, Federico
    Montorsi, Francesco
    Salonia, Andrea
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (03) : 339 - 344
  • [4] Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet
    Park, Sang-In
    Heo, Su-Hak
    Kim, Gihwan
    Chang, Seokhoon
    Song, Keon-Hyoung
    Kim, Min-Gul
    Jin, Eun-Heui
    Kim, JaeWoo
    Lee, SeungHwan
    Hong, Jang Hee
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 935 - 942
  • [5] Bioequivalence studies of film-coated tablet and chewable tablet generic formulations of montelukast in healthy volunteers
    Canovas, Mercedes
    Arcabell, Marta
    Martinez, Gemma
    Canals, Mireia
    Cabre, Francesc
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2011, 61 (11): : 610 - 616
  • [6] Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers
    Setiawati, Effi
    Yunaidi, Danang Agung
    Handayani, Lucia Rat
    Santoso, Iwan Dwi
    Setiawati, Mini
    Tjandrawinata, Raymond R.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2011, 61 (12): : 681 - 684
  • [7] Bioequivalence study of two different film-coated tablet formulations of losart-an-hydrochlorothiazide in healthy volunteers
    Neves, Rita
    Almedia, Susana
    Filipe, Augusto
    Franco Spinola, Ana Cristina
    Abolfathi, Zohreh
    Yritia, Mercedes
    Ortuno, Jordi
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2008, 58 (08): : 369 - 375
  • [8] EFFECTIVENESS AND SAFETY OF ORODISPERSIBLE SILDENAFIL IN A NEW FILM FORMULATION FOR THE TREATMENT OF ERECTILE DYSFUNCTION: COMPARISON BETWEEN SILDENAFIL 100 MG FILM-COATED TABLET (FCT) VS 75 MG ORODISPERSIBLE FILM (ODF)
    Cocci, A.
    Capece, M.
    Cito, G.
    Russo, G., I
    Falcone, M.
    Timpano, M.
    Rizzo, M.
    Della Camera, P. A.
    Cacciamani, G.
    Minervini, A.
    Gacci, M.
    Mondaini, N.
    Polloni, G.
    Serni, S.
    Natali, A.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : S252 - S253
  • [9] Post-marketing Safety of Two Different Formulations of Deferasirox, Film-Coated Tablet (FCT) and Dispersible Tablet (DT), A Comparative Assessment
    Velez-Nandayapa, L.
    Holder, G.
    Horowitz, J.
    Singal, R.
    Cortoos, A.
    Eisinger, J.
    DRUG SAFETY, 2016, 39 (10) : 1019 - 1019
  • [10] Bioequivalence studies of two different film-coated tablet formulations of valacyclovir of two different strengths in healthy volunteers
    Neves, Rita
    Almeida, Susana
    Filipe, Augusto
    Franco Spinola, Ana Cristina
    Abolfathi, Zohreh
    Levesque, Ann
    Ortuno, Jordi
    Torns, Alex
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2010, 60 (05): : 273 - 281